Co-Authors
This is a "connection" page, showing publications co-authored by CHRISTOPHER J LOGOTHETIS and CHAD HUFF.
Connection Strength
0.967
-
Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis. 2024 Jul 17.
Score: 0.242
-
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jul 01; 30(13):2751-2763.
Score: 0.241
-
Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer. 2024 Dec 01; 31(12).
Score: 0.062
-
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. 2024 Sep; 134(3):449-458.
Score: 0.060
-
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet. 2023 Dec; 55(12):2065-2074.
Score: 0.058
-
Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. Am J Hum Genet. 2023 07 06; 110(7):1200-1206.
Score: 0.056
-
Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry. medRxiv. 2023 May 15.
Score: 0.056
-
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer Prostatic Dis. 2022 04; 25(4):755-761.
Score: 0.051
-
Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 Mar; 53(3):413.
Score: 0.048
-
Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nat Commun. 2021 02 23; 12(1):1236.
Score: 0.048
-
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 01; 53(1):65-75.
Score: 0.047